Table 1 Patient characteristics, stratified according to age (n=1420)
Characteristic | ⩽ 50 years, n =292 | 51–70 years, n =895 | ⩾70 years, n =233 | |
|---|---|---|---|---|
Median age (range) in years | 46 (28–50) | 60 (51–69) | 73 (70–85) | |
n | n | n | P -value a | |
Pathologic T-stage | <0.001 b | |||
pT in situ | 6 (2.1%) | 31 (3.5%) | 7 (3.0) | |
pT1 | 177 (60.6%) | 667 (74.5%) | 175 (75.1) | |
pT⩾2 | 109 (37.3%) | 197 (22.0%) | 51 (21.9) | |
Pathologic N-stage | <0.001 | |||
pN0 | 182 (62.3%) | 633 (70.7%) | 188 (80.7) | |
pN+ | 104 (35.6%) | 234 (26.1%) | 40 (17.2) | |
pNx | 6 (2.1%) | 28 (3.1%) | 5 (2.1) | |
Tumour size | <0.001 | |||
⩽ 2 cm | 181 (62.2%) | 685 (76.9%) | 180 (77.3) | |
> 2 cm | 110 (37.8%) | 206 (23.1%) | 53 (22.7) | |
Axillary clearance | <0.001 | |||
No | 180 (61.6%) | 637 (71.2%) | 190 (81.5) | |
Yes | 112 (38.4%) | 258 (28.8%) | 43 (18.5) | |
Adjuvant systemic therapy | <0.001 | |||
No | 80 (27.4%) | 401 (44.8%) | 130 (55.8) | |
Endocrine treatment | 10 (3.4%) | 175 (19.6%) | 96 (41.2) | |
Chemotherapy | 51 (17.5%) | 100 (11.2%) | 5 (2.1) | |
Endocrine+chemotherapy | 151 (51.7%) | 219 (24.5%) | 2 (0.9) | |
Adjuvant trastuzumab | 0.001 | |||
No | 268 (91.8%) | 843 (94.2%) | 231 (99.1) | |
Yes | 24 (8.2%) | 52 (5.8%) | 2 (0.9) | |
Regional radiotherapy | 0.16 | |||
No | 269 (92.1%) | 835 (93.3%) | 224 (96.1) | |
Yes | 23 (7.9%) | 60 (6.7%) | 9 (3.9) | |
Co-morbidity | <0.001 | |||
Low | 273 (93.5%) | 769 (85.9%) | 173 (74.2) | |
Medium/high | 19 (6.5%) | 126 (14.1%) | 60 (25.8) |
